Drugs.com - Clinical Trials

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Apr 14, 2025 - 03:07
 0
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Read More

Tags:

Previous Article

Bangkok Is Calling: Rafat Ali and Brian Quinn on Travel’s Next Big Chapter

Next Article

Dryblower: gold soars and bonds crash in echoes of the '08 GFC

Related Posts

Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Chlamydia Vaccine Candidate Granted Fast Track Designat...

Mar 26, 2025  0

Lilly's Lepodisiran Reduced Levels of Genetically Inherited Heart Disease Risk Factor, Lipoprotein(a), by Nearly 94% from Baseline at the Highest Tested Dose in Adults with Elevated Levels

Lilly's Lepodisiran Reduced Levels of Genetically Inher...

Apr 1, 2025  0

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in the REDEFINE 2 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Mar 11, 2025  0